‘New GSK’ Still Has Some Convincing To Do
Vaccine And Speciality Medicines The Focus
Executive Summary
Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.
You may also be interested in...
New GSK To Leave Flagship HQ After Consumer Health Split
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.
Another Activist Investor Joins Calls For GSK Leadership Review
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.
‘New GSK’ Should Consider New CEO Too, Says Activist Investor
Elliott Advisors have said more pharma expertise on the board – including a possible new CEO – is the only way for GSK to restore investor confidence.